Skip to main content
Erschienen in: Neurological Sciences 7/2021

05.03.2021 | Letter to the Editor

Acute psychotic onset in LGI1-related limbic encephalitis

verfasst von: Francesca Notturno, Antonino Uncini

Erschienen in: Neurological Sciences | Ausgabe 7/2021

Einloggen, um Zugang zu erhalten

Excerpt

Leucine-rich glioma-inactivated 1 (LGI1)–related limbic encephalitis is a rare autoimmune disorder associated with antibodies to voltage-gated potassium channel complex that is infrequently accompanied by tumors and with a good response to therapy [1]. The onset and core symptoms are seizures and cognitive disorders. Seizures include generalized tonic-clonic seizures, partial seizures, and dystonia-like episodes involving face and limbs on the same side (FBDS). Among cognitive disorders, short-term memory impairment is the most common. We here describe a patient with LGI1-related encephalitis presenting with isolated acute psychosis. Additionally, we performed a PubMed search to identify papers reporting patients with LGI1-related encephalitis and psychiatric manifestations from January 2010 (the year of description of LGI1-related encephalitis) to May 2020 by using the following terms: LGI1 antibody, limbic encephalitis LGI1, combined with acute psychosis, psychiatric symptoms, and acute behavior disturbances. The search was restricted to full-text papers in English. …
Literatur
1.
Zurück zum Zitat Lai M, Huijbers MG, Lancaster E et al (2010) Investigation of LGl1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 9:776–785CrossRef Lai M, Huijbers MG, Lancaster E et al (2010) Investigation of LGl1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 9:776–785CrossRef
2.
Zurück zum Zitat Rodriguez A, Pittock S, McKeon A et al (2020) LGI1 antibody encephalitis: treatments and long-term outcome. Neurology 94(15 Supplement):3947 Rodriguez A, Pittock S, McKeon A et al (2020) LGI1 antibody encephalitis: treatments and long-term outcome. Neurology 94(15 Supplement):3947
3.
Zurück zum Zitat Le Dault E, Lagarde S, Guedj E et al (2016) Unexplicated neuropsychiatric disorders: do not ignore dysimmune encephalitis. A case report of a dysimmune encephalitis with anti-leucine rich glioma inactivated 1 (LGI-1) antibodies. Rev Med Interne 37:127–130CrossRef Le Dault E, Lagarde S, Guedj E et al (2016) Unexplicated neuropsychiatric disorders: do not ignore dysimmune encephalitis. A case report of a dysimmune encephalitis with anti-leucine rich glioma inactivated 1 (LGI-1) antibodies. Rev Med Interne 37:127–130CrossRef
4.
Zurück zum Zitat Wang D, Hao Q, He L, Wang Q (2018) LGI1 antibody encephalitis and psychosis. Australas Psychiatry. 26:612–614CrossRef Wang D, Hao Q, He L, Wang Q (2018) LGI1 antibody encephalitis and psychosis. Australas Psychiatry. 26:612–614CrossRef
5.
Zurück zum Zitat Kozik JM, Krzystanek M, Cichoń L et al (2017) An adolescent case of limbic encephalitis with anti leucine-rich glioma inactivated 1 antibodies. Neuropsychiatry 7:179–182 Kozik JM, Krzystanek M, Cichoń L et al (2017) An adolescent case of limbic encephalitis with anti leucine-rich glioma inactivated 1 antibodies. Neuropsychiatry 7:179–182
6.
Zurück zum Zitat MAAM DB, van Sonderen A, van Coevorden-Hameete MH et al (2019) Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis. Neurology 92:2185–2196CrossRef MAAM DB, van Sonderen A, van Coevorden-Hameete MH et al (2019) Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis. Neurology 92:2185–2196CrossRef
Metadaten
Titel
Acute psychotic onset in LGI1-related limbic encephalitis
verfasst von
Francesca Notturno
Antonino Uncini
Publikationsdatum
05.03.2021
Verlag
Springer International Publishing
Erschienen in
Neurological Sciences / Ausgabe 7/2021
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-021-05134-0

Weitere Artikel der Ausgabe 7/2021

Neurological Sciences 7/2021 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.